Gainers

• Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million.
• PDS Biotechnology (NASDAQ:PDSB) shares moved upwards by 40.95% to $0.31. The market value of their outstanding shares is at $12.3 million.
• Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 28.54% to $1.07.
• Turn Therapeutics (NASDAQ:TTRX) shares moved upwards by 25.61% to $12.31. The market value of their outstanding shares is at $297.6 million.
• Roivant Sciences (NASDAQ:ROIV) stock increased by 19.86% to $41.87. The market value of their outstanding shares is at $25.2 billion.
• Actinium Pharmaceuticals (AMEX:ATNM) stock rose 18.33% to $1.22. The company's market cap stands at $32.3 million.

Losers

• Lexaria Bioscience (NASDAQ:LEXX) shares decreased by 35.5% to $9.12 during Tuesday's regular session. The market value of their outstanding shares is at $23.3 million.
• bioAffinity Technologies (NASDAQ:BIAF) stock declined by 33.98% to $10.08. The company's market cap stands at $9.1 million.
• GRI Bio (NASDAQ:GRI) shares fell 29.52% to $2.03. The market value of their outstanding shares is at $6.2 million.
• Jaguar Health (NASDAQ:JAGX) stock decreased by 24.2% to $0.45. The company's market cap stands at $3.0 million.
• Gelteq (NASDAQ:GELS) stock fell 22.11% to $0.7. The market value of their outstanding shares is at $9.6 million.
• Atrium Therapeutics (NASDAQ:RNA) stock fell 20.58% to $11.27. The market value of their outstanding shares is at $242.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.